by The Immune Cell Engineering Market is estimated to be valued at US$ 2.82 Bn in 2023 and is expected to exhibit a CAGR of 22. % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Immune cell engineering includes techniques to modify the immune cells for enhanced activities to fight diseases. The techniques like genetic engineering, cell surface engineering and metabolic engineering are used to enhance the functions of immune cells like T cells, NK cells, dendritic cells etc. Immune cell engineering has wide applications in development of CAR T-cell therapy, cancer vaccines and other advanced immunotherapies.
Market key trends:
One of the key trends fueling the growth of immune cell engineering market is increasing adoption of CAR T-cell therapy and other advanced cell therapies. CAR T-cell therapy involves genetically engineering T cells taken from patients to express antigen-specific receptors called chimeric antigen receptors (CARs). CAR T-cell therapy has shown promising results in treatment of cancers like leukemia and lymphoma. Growing success of CAR T-cell therapy is driving considerable research to develop next generation CAR T-cells with enhanced efficacy and safety. Metabolic engineering of immune cells is another emerging trend to optimize immune cell therapies. Techniques like glycolytic reprogramming are being explored to improve effector functions and persistence of immune cells like CAR T-cells in host tissues.
Porter’s Analysis
Threat of new entrants: The immune cell engineering industry requires large capital investments and expertise that pose high entry barriers for new players.
Bargaining power of buyers: Buyers have high bargaining power due to availability of substitute therapies and products from multiple manufacturers.
Bargaining power of suppliers: A few leading biotech companies control key raw materials and technologies, giving them significant influence over pricing and supplies.
Threat of new substitutes: Emerging alternative therapies like oncolytic viruses and gene therapy pose threat of substitution.
Competitive rivalry: Strong competition exists among established players to gain greater market share through new product launches and strategic collaborations.
SWOT Analysis
Strength: Availability of advanced engineering technologies and established infrastructure for immune cell manufacturing.
Weakness: High costs associated with R&D, production and regulatory requirements limits market penetration. Scarcity of skilled professionals poses operational challenges.
Opportunity: Rapidly growing demand for cell therapies in oncology and infectious diseases indications present lucrative opportunities.
Threats: Stringent regulatory pathways and safety concerns over long term effects pose regulatory threats. Data security issues and IP thefts are risks.
Key Takeaways
The Global Immune Cell Engineering Market Growth is expected to witness high, exhibiting CAGR of 22% over the forecast period, due to increasing prevalence of cancer and infectious diseases. Advancements in cell engineering technologies are further fueling the market growth.
Regionally, North America dominates the market currently owing to availability of advanced healthcare facilities and presence of key industry players in the US. Asia Pacific is anticipated to exhibit fastest growth rate over next few years led by expanding research infrastructure in China, Japan and India.
Key players operating in the immune cell engineering market include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, Lonza Group, Miltenyi Biotec, Takara Bio Group, CellGenix GmbH, FUJIFILM Irvine Scientific, Agilent Technologies, Bio-Techne Corporation, Bio-Rad Laboratories, BD, Charles River Laboratories, Creative Bioarray, Sartorius AG, Novogene Corporation, AGC Biologics, Catalent, WuXi AppTec, ReachBio LLC. The players are engaged in new product launches, acquisitions and strategic collaborations with research institutes to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
